Jivoni Pharmax Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 01-11-2024
- Paid Up Capital ₹ 1.76 Cr
as on 01-11-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.96 Cr
as on 01-11-2024
- Revenue %
(FY 2023)
- Profit 4956.39%
(FY 2023)
- Ebitda 9467.85%
(FY 2023)
- Net Worth 473.98%
(FY 2023)
- Total Assets 1147.92%
(FY 2023)
About Jivoni Pharmax
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.76 Cr.
The company currently has active open charges totaling ₹17.96 Cr.
Muthulakshmi Gnanaguru and Mylsamy Thiruvenkataraj serve as directors at the Company.
- CIN/LLPIN
U51909TN2021PTC146694
- Company No.
146694
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2021
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Jivoni Pharmax?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muthulakshmi Gnanaguru  | Director | 30-Sep-2021 | Current |
| Mylsamy Thiruvenkataraj | Director | 21-Mar-2022 | Current |
Financial Performance and Corporate Structure Insights of Jivoni Pharmax.
Jivoni Pharmax Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 4956.39% increase in profit. The company's net worth Soared by an impressive increase of 473.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jivoni Pharmax?
In 2023, Jivoni Pharmax had a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shri Dhanyalakshmi Bioscience Private LimitedActive 11 years 3 monthsMuthulakshmi Gnanaguru is a mutual person
Jivoni Realty Management Private LimitedActive 21 years 5 monthsMuthulakshmi Gnanaguru is a mutual person
- Sri Navoji Trade Enterprise Private LimitedActive 2 years 2 months
Muthulakshmi Gnanaguru is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Sep 2023 | ₹0.92 M | Open |
Others Creation Date: 08 Sep 2023 | ₹5.15 Cr | Open |
Others Creation Date: 30 Aug 2023 | ₹3.90 Cr | Open |
How Many Employees Work at Jivoni Pharmax?
Jivoni Pharmax has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jivoni Pharmax, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jivoni Pharmax's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
